Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART …
SA Gatz, AC Harttrampf, C Brard, F Bautista… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and
activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and …
activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and …
The Association of PARP1 Enzymatic Inhibition and Chromatin Complex Formation with Radiosensitization by PARP Inhibitors and Their Combination with ATR …
C Engelke - 2022 - deepblue.lib.umich.edu
Pancreatic cancer has a five-year overall survival rate of less than 10%. Locoregional
progression is responsible for death in up to a third of all patients, highlighting the need for …
progression is responsible for death in up to a third of all patients, highlighting the need for …